NFKB1 and familial pancreatic carcinoma: Recent studies showed that NF-κB inhibitors in combination with cytotoxic compounds improved chemotherapy sensitivity in pancreatic cancer [97], and the inhibition of TRAF6/NF-κB p65/P-gp axis by miR-146a-5p suppressed PDAC cell proliferation and sensitized PDAC cells to gemcitabine chemotherapy [98].